Accurate prediction of Adverse Drug Reactions (ADRs) at the patient level is essential for ensuring patient safety and optimizing healthcare outcomes. Traditional machine learning-based methods primarily focus on predicting potential ADRs for drugs, but they often fall short of capturing the complexity of individual demographics and the variations in ADRs experienced by different people. In this study, a novel framework called Precise Adverse Drug Reaction (PreciseADR) for patient-level ADR prediction is proposed.
View Article and Find Full Text PDFDrug repurposing-identifying new therapeutic uses for approved drugs-is often a serendipitous and opportunistic endeavour to expand the use of drugs for new diseases. The clinical utility of drug-repurposing artificial intelligence (AI) models remains limited because these models focus narrowly on diseases for which some drugs already exist. Here we introduce TxGNN, a graph foundation model for zero-shot drug repurposing, identifying therapeutic candidates even for diseases with limited treatment options or no existing drugs.
View Article and Find Full Text PDFDeveloping personalized diagnostic strategies and targeted treatments requires a deep understanding of disease biology and the ability to dissect the relationship between molecular and genetic factors and their phenotypic consequences. However, such knowledge is fragmented across publications, non-standardized repositories, and evolving ontologies describing various scales of biological organization between genotypes and clinical phenotypes. Here, we present PrimeKG, a multimodal knowledge graph for precision medicine analyses.
View Article and Find Full Text PDFIEEE Trans Vis Comput Graph
January 2023
Whether AI explanations can help users achieve specific tasks efficiently (i.e., usable explanations) is significantly influenced by their visual presentation.
View Article and Find Full Text PDFAdverse drug reactions are the fourth leading cause of death in the US. Although women take longer to metabolize medications and experience twice the risk of developing adverse reactions compared with men, these sex differences are not comprehensively understood. Real-world clinical data provide an opportunity to estimate safety effects in otherwise understudied populations, i.
View Article and Find Full Text PDF